# Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients

> **NCT03281824** · PHASE1 · COMPLETED · sponsor: **Alteogen, Inc.** · enrollment: 27 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **BIOLOGICAL:** ALT-P7 (HM2-MMAE)

## Key facts

- **NCT ID:** NCT03281824
- **Lead sponsor:** Alteogen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-11
- **Primary completion:** 2020-03-12
- **Final completion:** 2021-01-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03281824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03281824, "Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03281824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*